Prognostic value of urinary 11‐dehydro‐thromboxane B₂ for mortality: A cohort study of stable coronary artery disease patients treated with aspirin

Abstract

Our data indicate the optimal cut point for urine 11dhTxB2 is 1597.8 (pg/mg) for the risk prediction of mortality over five years in stable patients with CAD patients treated with aspirin.

Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2

“…The 24-h excretion of urinary TXB2 in smokers was increased by 30% compared to non-smokers, while the amount of urinary TXB2 excreted adjusted for creatinine was increased by 45%. This is an important finding as levels of urinary TXB2 are associated with poorer prognosis in cardiovascular disease [ [39] , [40] , [41] , [42] ].…”

“…Measurements of systemic thromboxane A2 have been proven difficult to test because of the complexity of measuring its production in vivo , with an extremely short half-life [ 19 ], nevertheless, other ways of assessing thromboxane production in a less invasive manner include the determination of its urinary metabolites, one of which is TXB2 [ 48 ]. In actuality, TXB2 measurements are used as a prognostic tool in acute myocardial infarction patients [ 40 ], for mortality in patients with stable coronary artery disease [ 39 , 41 ] and as a marker of vascular inflammation and prognostic in atherosclerotic cardiovascular disease [ 42 ].…”